<DOC>
	<DOCNO>NCT01447394</DOCNO>
	<brief_summary>The purpose study determine 48 week therapy Pegylated Interferon Lambda plus Ribavirin effective safe treatment chronic hepatitis C ( CHC ) compare therapy Pegylated Interferon Alfa-2a plus Ribavirin .</brief_summary>
	<brief_title>Safety Efficacy Study Pegylated Interferon Lambda Versus Pegylated Interferon Alfa , Plus Ribavirin Subjects With Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Chronic hepatitis C , Genotype 1 4 HCV Ribonucleic acid ( RNA ) â‰¥ 100,000 IU/mL screen Liver biopsy document cirrhosis ( within prior 2 year ) cirrhosis ( time prior randomization ) . Where approve stag liver disease , noninvasive imaging may use assess extent liver disease . Subjects compensate cirrhosis enroll cap 10 % Naive prior antiHCV therapy Infected HCV Genotype 1 4 Positive Hepatitis B surface antigen ( HBsAg ) , Human immunodeficiency virus1 ( HIV1 ) /HIV2 antibody hepatitis D virus ( HDV ) screen Evidence liver disease HCV Active substance abuse Use hematologic growth factor within 90 day prior study randomization Evidence decompensated cirrhosis base radiologic criterion biopsy result clinical criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>